TP53 and diffuse large B-cell lymphoma: However, only one study conducted during the CHOP era analyzed the impact of the coexistence of TP53 mutation and deletion; the presence of both aberrations, but not only one of them, was determined to be a poor prognostic factor for DLBCL [27].